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Perspective
ovarian cancer in clinical complete remission and with a 
normal CA-125 following initial therapy. It found that 
using CA-125 surveillance every 3 months as the basis 
for recommencing treatment did not improve survival or 
quality of life. Importantly, it also found that women 
who received delayed treatment following the onset of 
symptoms reported a higher quality of life than those 
treated earlier.4
This study has been the subject of extensive analysis, Reconsidering the place of disease 
monitoring after treatmentom
ch
ha
marker cance
W en who have completed primary emotherapy for ovarian cancer commonly ve serial assessment of the serum tumour 
r antigen 125 (CA-125).1 This practice has 
been based on the proven utility of CA-125 in diagnostic 
algorithms and as a marker of response to therapy. Serial 
CA-125 assessment is also used because there is evidence 
that in women who have completed treatment for ovarian 
cancer, the serum CA-125 rises 2–6 months before 
symptoms or signs of relapse develop. The assumption 
underlying this and other similar studies is that serial 
monitoring of CA-125 would enable early diagnosis and 
treatment of relapse. This would thus lead to delay or 
reduction of cancer-related symptoms, psychological 
reassurance and, in theory, improved survival.1
Some studies have suggested that CA-125 may have 
some benefit in post-treatment surveillance. However, 
many others have demonstrated that although a rising 
CA-125 level is highly predictive of relapse, surveillance 
monitoring of CA-125 levels after remission from 
primary chemotherapy confers little benefit over 
standard clinical examination and does not improve 
duration of survival or quality of life.2,3
There are many possible explanations for the apparently 
conflicting data regarding the merits of CA-125 
surveillance following initial ovarian cancer therapy. These 
include the stage of the primary cancer, the choice of 
chemotherapy, the definition of remission, and the timing 
and frequency of surveillance testing. In spite of this, those 
caring for women with ovarian cancer have no clear 
guidance regarding the place of CA-125 surveillance.
The results of a recent randomised controlled trial 
(RCT) published in The Lancet present a further challenge 
to the routine practice of CA-125 surveillance.4 This 
study, by Rustin and colleagues, included 1442 women 
from 59 medical centres across Europe with stage I–IV 
with critics identifying several potential confounding 
factors in the study design and analysis and questioning 
the results.5 These include the heterogeneity of the study 
population, the time taken to complete the study (10 
years), the number of collaborators (128), the statistical 
analysis, the lack of standardisation of surgical debulking 
and management of recurrence, and the choice of 
outcome measures. Although there are unquestionably 
deficiencies in the Rustin study, it was a blinded RCT 
that directly assessed the effect of treatment decisions 
made on the basis of CA-125 testing on health outcomes 
(mortality and quality of life). This means that it should 
be taken seriously and that we should (re)consider how 
it is that CA-125 surveillance became part of the routine 
management of ovarian cancer.
Understanding the “drivers” of CA-125 
surveillance
A review of follow-up testing of patients with lung 
cancer suggested several reasons why doctors may use 
more intensive follow-up testing than can be justified. 
These include an overoptimistic assessment of the 
benefits of early diagnosis of relapse and/or the value of 
follow-up testing, and an explicit or implicit desire to 
avoid discussions about futility and the active 
management of terminal illness.6 Thus, using only 
clinical examination and the patient’s history may seem 
inconsistent with good medical practice (regardless of 
the evidence), when, for example, in the case of ovarian 
cancer, a doctor can also use a CA-125 test to gain 
further information about the patient’s disease.
Doctors may also feel that their patients lack faith in 
the validity of their own symptoms, and want objective, 
scientific data about their disease. They want to be 
reassured that close monitoring may enable early 
diagnosis and treatment of a relapse. Finally, doctors 
may feel that most women with ovarian cancer know (or 
will find out) that CA-125 testing exists, and believe that 
its level correlates with disease status, and so will expect 
surveillance testing to be done.
Similarly, patients may simply go along with the 
management plan developed by their doctor because 
they fear recurrence or progressive disease more than the 
anxiety associated with surveillance. They may also be 
willing to experience any inconvenience, side effect or 
toxicity for even a small chance of benefit.6 Women with 
advanced ovarian cancer, in particular, may also deeply 
distrust their own body and feel (often rightly) that 
relapse is inevitable.
Qualitative studies of patients who have completed 
treatment for other cancers support the idea that 
patients may wish to make use of post-therapy 
surveillance because it assists them in dealing with 
uncertainty and with the anxiety of relapse.7
Serial CA-125 testing may allow women to “manage” 
the uncertainty and anxiety surrounding their disease 
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Perspectivesstatus, their bodies and their lives, because a “good” 
result will be reassuring, and even a “bad” result may 
provide some ordered foreknowledge that some women 
may find helpful.7 The results of CA-125 tests may 
therefore help predict the future of the disease, 
determine interventions, provide a framework for action 
and legitimise the illness. CA-125 test results may help a 
patient achieve a sense of order in a body she may have 
learnt not to trust, and help her define her social roles 
and relationships.7
Implications for practice
What role does CA-125 surveillance have in 
asymptomatic women with ovarian cancer? Intensive 
surveillance, including CA-125 monitoring, would be 
desirable if early recognition and treatment of relapse 
produced a meaningful survival benefit or improved 
quality of life. The evidence suggests that it does not, so 
there appear to be two options for the use of CA-125 in 
surveillance outside clinical trials.
The first option is to recommend that CA-125 
monitoring should not be routinely performed following 
treatment for ovarian cancer. This approach is consistent 
with the published clinical and epidemiological evidence 
and would be economically prudent. It would 
undoubtedly attract some controversy, but would be 
consistent with similar recommendations against the use 
of other tumour markers such as carcinoembryonic 
antigen, cancer antigen 15-3 and cancer antigen 27.29 in 
surveillance after primary treatment of breast cancer.8
The second option would be to accept that oncologists 
and patients may reasonably make a shared decision to 
incorporate CA-125 monitoring into their post-
treatment care, on the understanding that CA-125 
monitoring may not confer any advantage to survival or 
quality of life. This approach recognises the many 
reasons why a patient or doctor may want to perform 
surveillance testing. It also recognises that, although 
rising CA-125 levels alone should not dictate therapy, 
they may provide a point when goals of care can be 
re-examined. This approach explicitly acknowledges that 
women may make very different decisions about their 
care. Some may choose to have diagnostic testing and 
treatment only when they become symptomatic, and 
others may choose to have CA-125 surveillance and to 
have treatment even when they are asymptomatic, and 
irrespective of adverse effects.9
This second approach to post-treatment use of 
CA-125 surveillance is consistent with clinical guidelines 
(currently being revised in the light of emergent data on 
CA-125 surveillance).10 The ongoing use of a surveillance 
measure for reasons other than improving survival or 
quality of life may also be more acceptable to patients, 
clinicians and the health system if, as suggested by 
Rettenmaier and colleagues, it is not economically 
prohibitive.2
Rustin and colleagues from the European 
Organisation for Research and Treatment of Cancer 
deserve congratulation for designing and completing a 
seminal study, not only in ovarian cancer, but in 
oncology generally. The conclusion that earlier therapy 
of relapse detected by CA-125 with current treatments 
does not prolong survival seems rock solid, and demands 
an end to the practice of routine CA-125 surveillance in 
ovarian cancer.
This does not mean, though, that CA-125 testing has 
no role in surveillance, as it may provide some benefit 
beyond mortality and morbidity — something that 
should now be the focus of rigorous qualitative study. In 
the interim, oncologists should openly discuss the 
options for monitoring disease following primary 
therapy with their patients, and should use clinical 
follow-up and the results of surveillance testing (if they 
choose to do it) in advance care planning.
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